Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry

Siddharth M. Patel, MD, MPH,1 David D. Berg, MD, MPH,1 Erin A. Bohula, MD, DPhil,1 Vivian M. Baird-Zars, MPH,1 Jeong-Gun Park, PhD,1 Jason N. Katz, MD, MHS,2 Sean van Diepen, MD, MSc,3 David A. Morrow, MD, MPH,1 for the CCCTN Investigators

1TIMI Study Group, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA, USA; 2Division of Cardiology, Department of Medicine, New York University, New York, NY, USA; 3Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

BACKGROUND

- Vasoactive agents (e.g., vasopressors or inotropes), are routinely employed as 1st line therapy for cardiogenic shock (CS).
- The intensity of pharmacologic support may be used as a marker of CS severity and as an independent correlate of mortality.
- CS is a dynamic state, in which iterative assessment of overall trajectory may influence clinical assessment of severity and decision making for therapies.
- Relationships between early changes in aggregate vasoactive burden and outcomes in CS are not well-defined.

METHODS

- CCUs in the Critical Care Cardiology Trials Network (CCCTN) contribute all consecutive medical admissions in annual 2-month ‘snap-shots’, with subset reporting shock admissions year-round.
- Dosing of all vasoactive agents was captured in the electronic case record form at 4h and 24h from CICU admission.
- The vasoactive-inotropic score (VIS) was used to quantify the intensity of vasoactive support at each time point.
  - VIS = dobutamine + dopamine + 10*phenylephrine + 10*milrinone + 100*epinephrine + 100*norepinephrine + 10,000*vasopressin (in µg/kg/min [or U/kg/min])
  - A VIS of 10 = norepinephrine or epinephrine at a dose of 8 µg/min in an 80-kg patient
- Associations between change in VIS from 4h to 24h with CICU mortality, were examined categorically using previously applied thresholds and continuously per 10-point increase in VIS.
- Discrimination of CICU mortality by change in VIS was contrasted with the 24h SOFA score and clinician-determined SCAI stage.

RESULTS

- A total of 3,665 patients who presented with CS with available VIS at 4h and 24h were included.
- Examining associations at static timepoints, CICU mortality increased stepwise for across both 4h and 24h VIS values (13% to 45% and 11% to 73% for VIS <10 vs. ≥40; p-trend < 0.0001).
- Stratifying by the 4h VIS, a greater proportion of those with higher starting VIS at 4h had decreases ≥10 by 24h (Fig 1A).
- Change in VIS from 4h to 24h had good discrimination of CICU mortality (C-stat 0.72 [0.70-0.75]), and improved discrimination of: 24h SOFA score: C-stat 0.72 (0.69-0.74) to 0.76 (0.74-0.78) 24h SCAI stage: C-stat 0.72 (0.70-0.74) to 0.77 (0.75-0.79)

CONCLUSIONS

- Early changes in the magnitude of vasoactive support in CS are associated with a gradient of risk for CICU mortality and provide incremental prognostic information.
- These data suggest that early vasoactive trajectory, which may be seamlessly integrated into EHRs, can improve CS prognostication, with potential to be leveraged for clinical decision-making and research applications in CS.

Full Manuscript Online @ Circ HF →

DISCLOSURE OF FACULTY RELATIONSHIPS

The authors report no relevant conflicts of interest.

Figure 1: Distribution of Change in VIS by Initial 4h VIS

Figure 2: Probability of CICU Mortality by Continuous Change in VIS